Earnings

While quarterly revenues show ups and downs in each region, Lupin is set on continued growth, with a touch of complexity and innovation – including shifting its thinking on the attractiveness of biosimilars.

While biosimilars updates were thin on the ground as Biogen reported its full-year results, the segment nevertheless reported growth in 2024. Meanwhile, the firm also offered some comments on how it saw generic and biosimilar competition to its Tecfidera and Tysabri multiple sclerosis brands playing out this year.

A US tariff on imports from China raises the spectre of similar action against India, but Aurobindo, the largest generics company in the US by prescriptions dispensed, assures it has alternatives in place. While trials for an opthalmology biosimilar are delayed, supply of other biosimilars to Europe is set to begin in Q2 FY26.

Zydus’ latest results faced scrutiny from industry analysts due to a mixed performance where weaker revenue in the Indian company’s domestic market was offset by growth in the US. Meanwhile, the firm has just agreed a deal with Synthon for a 505(b)(2) hybrid product in the US.

Biocon Biologics’ management shared updates regarding their facilities, expansion, and fast upcoming ustekinumab biosimilar launch in the US. Also, Biocon made a final acquisition payment to Viatris, while increasing its stake in the biosimilars business.

India’s Gland Pharma had much to discuss during its financial third-quarter earnings call, including a recent CDMO partnership with China’s Shanghai Henlius Biotech that could lead to the establishment of further manufacturing space to meet demand.

Speaking during its financial Q3 earnings call, Sun Pharma’s management has again pooh-poohed any idea of jumping into biosimilars in the near future, while providing updates on its trio of stricken Indian manufacturing facilities.

Amgen’s biosimilar sales grew by 16% last year, and with multiple candidates either due to launch or in the clinic, the firm is showing no signs of slowing down on its aspirations.

Biocon reported another quarter of sluggish generics revenues but hopes that planned generic liraglutide launches and US facility expansion will grow this business segment.

Slovenian firm Krka addressed concerns about potential capacity restrictions during its recent preliminary annual earnings call, stating that it was continuing to work with partners while maintaining its own investments to meet its goals.

Teva will look to its continued investments in complex generics and biosimilars to support continued top-line growth in 2025 and 2026, as the Israeli firm discussed during a busy year-end earnings call.

J&J’s fourth-quarter and full-year results have confirmed the decline for Stelara that had already begun to be seen late last year. And with US biosimilars now set to take a slice of the ustekinumab market following the launch of multiple European rivals last year, for the originator the only way is down.

India’s Torrent managed to register growth in its financial third quarter – despite being hit by severe currency headwinds in Brazil and suffering a decline in the US – as growth in Germany and its domestic market more than offset the damage.

In a thorough financial Q3 earnings call, generics and biosimilars giant Dr Reddy’s revealed several key details about its plans to “be in the neighborhood for some time” with a 25%+ EBITDA margin, including through the planned near- and medium-term launches of denosumab, abatacept and semaglutide.

Samsung Bioepis has reported a major boost to its operating results in 2024, lifted by biosimilar launches that included its Pyzchiva rival to Stelara in Europe through partner Sandoz, which the firm says has gained the largest market share among ustekinumab challengers.

Sawai has teed up multiple new launches in Japan after reporting the listing of five generics across ten presentations in the country’s National Health Insurance drug price list. The new registrations come after the firm reported lukewarm first-half results amid ongoing domestic supply issues.

Gedeon Richter is feeling good about its plan to launch a biosimilar denosumab product in the EU in 2025, as it continued to slow down losses for its biopharma unit ahead of plans to swing to profitability later in the decade.

Celltrion’s focus on European expansion has paid off but is overshadowed by “lackluster” Zymfentra revenues in the US.

Amphastar’s leadership has discussed its strategy and latest results as part of a fireside chat at this year’s Jefferies Healthcare Conference, restating its expectations of potential approvals of its GLP-1 candidate in 2025.